A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors - Concepedia

Concepedia

Publication | Closed Access

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

118

Citations

7

References

2007

Year

Elisabeth I. Heath, Keith C. Bible, Robert E. Martell, Daniel C. Adelman, Patricia LoRusso

Investigational New Drugs

Cyclin-dependent Kinases 2OncologyMedicineWeekly InfusionAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyPhase 1

References

	Year	Citations

Page 1